Debiopharm continues the fight against antibiotic resistance with investment in ABAC Therapeutics Inc. / ABAC develops new targeted antibiotics for patients with severe infections

Lausanne (ots) - Debiopharm Group (TM) announces an investment in
antibiotic development with the acquisition of a minority stake in
ABAC Therapeutics Inc. This investment was made through the
Debiopharm Innovation Fund, its strategic investment fund, and
illustrates the synergy between the group companies in the fight
against the worrying emergence of antibiotic resistance.

Debiopharm International, the drug development company of the
Group, is developing targeted antibiotics that represent the future
of treating bacterial infections. Its pipeline is based on afabicin
(Debio 1450), the first selective antibiotic against Staphylococci,
currently in advanced development for skin and bone infections, as
well as two earlier stage projects (Debio 1453 and Debio 1454)
against multidrug-resistant pathogens among the WHO and CDC priority
targets.

ABAC shares this vision of precision medicine in the treatment of
infectious diseases. Their PasNas research platform makes it possible
to identify new targeted molecules and their most advanced program
targets Acinetobacter, whose resistant forms are at the origin of
many infections that are very difficult to treat. Their research
skills are complementary to Debiopharm's expertise in pharmaceutical
development.

"We are delighted with our investment in ABAC. The main focus of
Debiopharm Innovation Fund's investments is smart data, but we also
invest in pharmaceutical and diagnostic companies that are
strategically important to Debiopharm Group. Just like us, ABAC is
tackling antibiotic resistance," explains Thierry Mauvernay,
President of Debiopharm Group.

About Debiopharm Group(TM)

Debiopharm Group, is an international biopharmaceutical group
headquartered in Switzerland, including five life science companies
that are developing drugs, manufacturing proprietary GMP medicines
and diagnostic tools, as well as in the management of investments.

For more information, please visit our website www.debiopharm.com

We are present on Twitter. Follow us @DebiopharmNews:
http://twitter.com/DebiopharmNews

Pressekontakt:
Christelle von Büren
Communication Coordinator
christelle.vonburen@debiopharm.com
Tel: +41 (0)21 321 01 11

Original-Content von: Debiopharm International SA, übermittelt durch news aktuell